582 related articles for article (PubMed ID: 19033371)
21. DISCORDANCE BETWEEN GH AND IGF-1 LEVELS IN TURKISH ACROMEGALIC PATIENTS.
Cerit ET; Ağbaht K; Demir Ö; Şahin M; Gedik VT; Özcan C; Çorapçıoğlu D
Endocr Pract; 2016 Dec; 22(12):1422-1428. PubMed ID: 27631850
[TBL] [Abstract][Full Text] [Related]
22. Gender and age in the biochemical assessment of cure of acromegaly.
Freda PU; Landman RE; Sundeen RE; Post KD
Pituitary; 2001 Aug; 4(3):163-71. PubMed ID: 12138989
[TBL] [Abstract][Full Text] [Related]
23. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
[TBL] [Abstract][Full Text] [Related]
24. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.
Dimaraki EV; Jaffe CA; DeMott-Friberg R; Chandler WF; Barkan AL
J Clin Endocrinol Metab; 2002 Aug; 87(8):3537-42. PubMed ID: 12161471
[TBL] [Abstract][Full Text] [Related]
25. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.
Freda PU; Nuruzzaman AT; Reyes CM; Sundeen RE; Post KD
J Clin Endocrinol Metab; 2004 Feb; 89(2):495-500. PubMed ID: 14764751
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
Freda PU; Post KD; Powell JS; Wardlaw SL
J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
[TBL] [Abstract][Full Text] [Related]
27. Value of early postoperative random growth hormone levels and nadir growth hormone levels after oral glucose tolerance testing in acromegaly.
Rotermund R; Burkhardt T; Rohani Z; Jung R; Aberle J; Flitsch J
Growth Horm IGF Res; 2018 Aug; 41():64-70. PubMed ID: 29555234
[TBL] [Abstract][Full Text] [Related]
28. Assessment of biochemical control of acromegaly during treatment with somatostatin analogues by oral glucose load and insulin-like growth factor I.
Scacchi M; Carzaniga C; Vitale G; Fatti LM; Pecori Giraldi F; Andrioli M; Cattaneo A; Cavagnini F
J Endocrinol Invest; 2011 Oct; 34(9):e291-5. PubMed ID: 21697649
[TBL] [Abstract][Full Text] [Related]
29. Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study.
Carosi G; Mangone A; Sala E; Del Sindaco G; Mungari R; Cremaschi A; Ferrante E; Arosio M; Mantovani G
Eur J Endocrinol; 2021 Jul; 185(2):289-297. PubMed ID: 34081617
[TBL] [Abstract][Full Text] [Related]
30. Factors determining the long-term outcome of surgery for acromegaly.
Osman IA; James RA; Chatterjee S; Mathias D; Kendall-Taylor P
QJM; 1994 Oct; 87(10):617-23. PubMed ID: 7987657
[TBL] [Abstract][Full Text] [Related]
31. Hormonal diagnosis of GH hypersecretory states.
Grottoli S; Gasco V; Ragazzoni F; Ghigo E
J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
[TBL] [Abstract][Full Text] [Related]
32. Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly.
Bourdelot A; Coste J; Hazebroucq V; Gaillard S; Cazabat L; Bertagna X; Bertherat J
Eur J Endocrinol; 2004 Jun; 150(6):763-71. PubMed ID: 15191345
[TBL] [Abstract][Full Text] [Related]
33. Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1.
Parfitt VJ; Flanagan D; Wood P; Leatherdale BA
Clin Endocrinol (Oxf); 1998 Nov; 49(5):647-52. PubMed ID: 10197081
[TBL] [Abstract][Full Text] [Related]
34. Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria.
Hazer DB; Işık S; Berker D; Güler S; Gürlek A; Yücel T; Berker M
J Neurosurg; 2013 Dec; 119(6):1467-77. PubMed ID: 24074496
[TBL] [Abstract][Full Text] [Related]
35. [Acromegaly].
Chanson P
Presse Med; 2009 Jan; 38(1):92-102. PubMed ID: 19004612
[TBL] [Abstract][Full Text] [Related]
36. Treatment results of acromegaly as analyzed by different criteria.
van Lindert E; Hey O; Boecher-Schwarz H; Perneczky A
Acta Neurochir (Wien); 1997; 139(10):905-12; discussion 912-3. PubMed ID: 9401649
[TBL] [Abstract][Full Text] [Related]
37. Are there alternative tests for diagnosis of acromegaly?
Popovic V
J Endocrinol Invest; 2005; 28(11 Suppl International):73-4. PubMed ID: 16625850
[TBL] [Abstract][Full Text] [Related]
38. Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery.
Rubeck KZ; Madsen M; Andreasen CM; Fisker S; Frystyk J; Jørgensen JO
Eur J Endocrinol; 2010 Nov; 163(5):717-26. PubMed ID: 20813787
[TBL] [Abstract][Full Text] [Related]
39. Measurement of basal growth hormone (GH) is a useful test of disease activity in treated acromegalic patients.
Jayasena CN; Wujanto C; Donaldson M; Todd JF; Meeran K
Clin Endocrinol (Oxf); 2008 Jan; 68(1):36-41. PubMed ID: 18088288
[TBL] [Abstract][Full Text] [Related]
40. Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated IGF-1 but normal glucose-suppressed growth hormone.
Subbarayan SK; Fleseriu M; Gordon MB; Brzana JA; Kennedy L; Faiman C; Hatipoglu BA; Prayson RA; Delashaw JB; Weil RJ; Hamrahian AH
Endocr Pract; 2012; 18(6):817-25. PubMed ID: 22784832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
